Therapy Detail

Therapy Name Pazopanib
Therapy Description

Votrient (pazopanib) inhibits VEGFR-1, -2 and -3, KIT, and PDGFR, and FGFR1, 2, and 3, leading to decreased tumor angiogenesis and growth (PMID: 17620431, PMID: 23786770). Votrient (pazopanib) is approved for renal cell carcinoma and soft tissue sarcoma (FDA.gov).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Pazopanib Votrient GW-786034 FGFR1 Inhibitor 21 FGFR2 Inhibitor 15 FGFR3 Inhibitor 12 KIT Inhibitor 48 PDGFR Inhibitor (Pan) 27 VEGFR Inhibitor (Pan) 29 Votrient (pazopanib) inhibits VEGFR-1, -2 and -3, KIT, and PDGFR, and FGFR1, 2, and 3, leading to decreased tumor angiogenesis and growth (PMID: 17620431, PMID: 23786770). Votrient (pazopanib) is approved for renal cell carcinoma and soft tissue sarcoma (FDA.gov).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown synovial sarcoma not applicable Pazopanib Clinical Study Actionable In a retrospective study, Votrient (pazopanib) treatment resulted in median progression free survival of 16.4 weeks and median survival of 10.6 months in patients with synovial sarcoma (PMID: 26970174). 26970174
Unknown unknown non-small cell lung carcinoma not applicable Pazopanib Phase II Actionable In a Phase II trial, Votrient (pazopanib) treatment resulted in 86% (30/35) of patients with non-small cell lung cancer experiencing a decrease in tumor size, including one patient with a greater than 50% reduction, and resulted in a partial response based on RECIST criteria in three patients (PMID: 20516450). 20516450
Unknown unknown gastrointestinal neuroendocrine tumor not applicable Pazopanib Clinical Study Actionable In a clinical study, Votrient (pazopanib) treatment in patients with gastroenteropancreatic neuroendocrine tumors resulted in an overall response rate of 24% (19/124), stable disease in 39.5% (49/124), a progression free survival of 36% at six months, and a median overall survival of 10.2 months (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 446P). detail...
Unknown unknown Advanced Solid Tumor not applicable Pazopanib Phase I Actionable In a Phase I trial, Votrient (pazopanib) demonstrated safety and efficacy in a variety of pediatric solid tumors (PMID: 23857966). 23857966
Unknown unknown Advanced Solid Tumor not applicable Pazopanib Phase I Actionable In a Phase I study, Votrient (pazopanib) in combination with Taxol (paclitaxel) and Paraplatin (carboplatin) demonstrated efficacy in solid tumors (PMID: 22679111). 22679111
Unknown unknown uterine corpus sarcoma not applicable Pazopanib Clinical Study Actionable In a retrospective clinical study, Votrient (pazopanib) treatment resulted in objective response in 29% (10/35) and stable disease in 31% (11/35) of patients with uterine sarcoma, with median progression-free survival of 5.8 months and overall survival of 20.0 months (PMID: 29185261). 29185261
Unknown unknown clear cell renal cell carcinoma not applicable Pazopanib Phase II Actionable In a Phase II trial, 84% (84/100) of patients with renal clear cell cancer demonstrated a clinical benefit, which included a median tumor reduction of 14.4%, when treated with Votrient (pazopanib) prior to a planned nephrectomy (PMID: 27254750). 27254750
Unknown unknown clear cell renal cell carcinoma not applicable Pazopanib Phase III Actionable In a Phase III trial, Votrient (pazopanib) did not result in a significantly improved disease free survival compared to placebo in patients with renal clear cell carcinoma (PMID: 28902533). 28902533
Unknown unknown leiomyosarcoma not applicable Pazopanib Clinical Study Actionable In a retrospective study, Votrient (pazopanib) treatment resulted in median progression free survival of 18.6 weeks and median survival of 20.1 months in patients with leiomyosarcoma (PMID: 26970174). 26970174
Unknown unknown gastrointestinal stromal tumor not applicable Pazopanib Phase II Actionable In a Phase II trial, treatment with Votrient (pazopanib) plus best supportive care (BSC) resulted in improved progression-free survival (45% at 4 months) compared to BSC alone (15% at 4 months) in patients with Gleevec (imatinib) and Sutent (sunitinib)-resistant gastrointestinal stromal tumors (J Clin Oncol 33, 2015 (suppl; abstr 10506)). detail...
TP53 mutant sarcoma sensitive Pazopanib Clinical Study Actionable In a retrospective study, advanced sarcoma patients with TP53 mutations displayed improved progression-free survival (208 days versus 136 days) relative to patients with wild-type TP53 when treated with Votrient (pazopanib) (PMID: 26646755). 26646755
Unknown unknown fibrous histiocytoma not applicable Pazopanib Clinical Study Actionable In a retrospective study, Votrient (pazopanib) treatment resulted in median progression free survival of 15.3 weeks and median survival of 9.5 months in patients with undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma (PMID: 26970174). 26970174
Unknown unknown renal cell carcinoma not applicable Pazopanib FDA approved Actionable In a Phase III trial that supported FDA approval, Votrient (pazopanib) improved progression free survival in patients with advanced renal cell carcinoma (PMID: 20100962). detail... 20100962
Unknown unknown renal cell carcinoma not applicable Pazopanib Phase III Actionable In a Phase III trial, adjuvant Votrient (pazopanib) therapy post nephrectomy did not improve disease-free survival (HR=0.862, p=0.165) compared to placebo in patients with renal cell carcinoma (J Clin Oncol 35, 2017 (suppl; abstr 4507)). detail...
FGFR1 amp Her2-receptor negative breast cancer sensitive Pazopanib Clinical Study Actionable In a clinical case study, a patient with ERBB2 (HER2)-receptor negative breast cancer harboring FGFR1 amplification demonstrated antitumor activity when treated with Votrient (pazopanib), including a near complete loss of brain lesions and improved function of the liver (PMID: 29223982). 29223982
Unknown unknown uterus leiomyosarcoma not applicable Pazopanib Clinical Study Actionable In a retrospective clinical study, 33% (9/27) of patients with uterine leiomyosarcoma responded to Votrient (pazopanib) treatment (PMID: 29185261). 29185261
FGFR3-TACC3 urinary bladder cancer sensitive Pazopanib Preclinical Actionable In a preclinical study, bladder cancer cells harboring FGFR3-TACC3 demonstrated sensitivity to Votrient (pazopanib) in culture (PMID: 23558953). 23558953
FGFR3 R248C Advanced Solid Tumor sensitive Pazopanib Preclinical - Cell culture Actionable In a preclinical study, Votrient (pazopanib) inhibited growth of transformed cells expressing FGFR3 R248C in culture (PMID: 23786770). 23786770
FGFR2 K660N Advanced Solid Tumor sensitive Pazopanib Preclinical - Cell culture Actionable In a preclinical study, Votrient (pazopanib) inhibited growth of transformed cells expressing FGFR2 K660N in culture (PMID: 23786770). 23786770
Unknown unknown liposarcoma not applicable Pazopanib Clinical Study Actionable In a retrospective study, Votrient (pazopanib) treatment resulted in median progression free survival of 8 weeks and median survival of 7.3 months in patients with liposarcoma (PMID: 26970174). 26970174
FGFR2 P253R head and neck squamous cell carcinoma predicted - sensitive Pazopanib Clinical Study Actionable In a case study, treatment with Votrient (pazopanib) resulted in reduced tumor size in a patient with head and neck squamous cell carcinoma harboring FGFR2 P253R (PMID: 23786770). 23786770
FGFR3 S249C renal pelvis transitional cell carcinoma predicted - sensitive Pazopanib Clinical Study Actionable In a case study, a patient with urothelial carcinoma of the renal pelvis harboring FGFR3 S249C demonstrated a partial response lasting 9 months following treatment with Votrient (pazopanib) (PMID: 27271022). 27271022
Unknown unknown breast cancer not applicable Pazopanib Phase II Actionable In a Phase II trial, Votrient (pazopanib) displayed safety and some efficacy in breast cancer patients (PMID: 20682606). 20682606
FGFR2 W290C Advanced Solid Tumor sensitive Pazopanib Preclinical - Cell culture Actionable In a preclinical study, Votrient (pazopanib) inhibited growth of transformed cells expressing FGFR2 W290C in culture (PMID: 23786770). 23786770
FGFR2 K660E Advanced Solid Tumor sensitive Pazopanib Preclinical - Cell culture Actionable In a preclinical study, Votrient (pazopanib) inhibited growth of transformed cells expressing FGFR2 K660E in culture (PMID: 23786770). 23786770
Unknown unknown sarcoma not applicable Pazopanib Clinical Study Actionable In a retrospective study, Votrient (pazopanib) treatment resulted in median progression free survival of 15.4 weeks and median survival of 11.2 months in patients with soft tissue sarcoma (PMID: 26970174). 26970174
Unknown unknown sarcoma not applicable Pazopanib FDA approved Actionable In a Phase III trial that supported FDA approval, Votrient (pazopanib) improved progression free survival in patients with advanced soft tissue sarcoma (PMID: 22595799). detail... 22595799
Unknown unknown germ cell cancer not applicable Pazopanib Phase II Actionable In a Phase II trial, Votrient (pazopanib) treatment resulted in partial responses in 4.7% (2/43), stable disease in 44.2% (19/43), and a 3-month progression free survival probability of 12.8% in patients with refractory germ cell cancer (PMID: 28383677). 28383677
KRAS G12R thyroid cancer sensitive Pazopanib Preclinical - Cell line xenograft Actionable In a preclinical study, Votrient (pazopanib) inhibited Erk activation and growth of thyroid cancer cells harboring KRAS G12R in culture, and reduced tumor size in cell line xenograft models (PMID: 26324075). 26324075
Clinical Trial Phase Therapies Title Recruitment Status
NCT03334409 Phase II Pazopanib Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery Recruiting
NCT02788201 Phase II Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifine Crizotinib Dactinomycin Temsirolimus Vorinostat romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma Recruiting
NCT01599832 Phase I Pazopanib Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer Terminated
NCT01407562 Phase I Carboplatin Paclitaxel Pazopanib Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors Active, not recruiting
NCT01462630 Phase II Pazopanib Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma Recruiting
NCT02049905 Phase III Dacarbazine Doxorubicin Ifosfamide Pazopanib Aldoxorubicin Gemcitabine + Docetaxel Phase 3 Study to Treat Patients With Soft Tissue Sarcomas Completed
NCT01468922 Phase I Tivantinib Pazopanib Pazopanib and ARQ 197 for Advanced Solid Tumors Completed
NCT01841736 Phase II Pazopanib Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors Active, not recruiting
NCT01330966 Phase II Pazopanib Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma Completed
NCT02180867 Phase II Pazopanib Doxorubicin + Ifosfamide Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can be Removed by Surgery (PAZNTIS) Active, not recruiting
NCT02956798 Phase II Pazopanib Pazopanib Vs. Local Therapy for Renal Cancer With Metastases Recruiting
NCT01361113 Phase II Pazopanib Neoadjuvant Pazopanib in Renal Cell Carcinoma Completed
NCT01217931 Phase II Everolimus Pazopanib Bevacizumab Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy Active, not recruiting
NCT02406521 Phase I Pazopanib radium Ra 223 dichloride Sorafenib Exploratory Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases Active, not recruiting
NCT01506596 Pazopanib Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma Completed
NCT01956669 Phase II Pazopanib Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors Recruiting
NCT01221506 Phase I Pazopanib Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC) Completed
NCT01552356 Phase I Pazopanib Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors Active, not recruiting
NCT01832259 Phase II Pazopanib A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection Completed
NCT03592472 Phase III Pazopanib Pazopanib + Abexinostat A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) Recruiting
NCT02009449 Phase I Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin nab-paclitaxel A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors Active, not recruiting
NCT01466972 Phase II Pazopanib Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib Active, not recruiting
NCT01759303 Phase II Pazopanib Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung Terminated
NCT02193152 Phase I Pazopanib Pazopanib in Molecularly Selected Patients With Advanced NSCLC Active, not recruiting
NCT01236547 Phase II Paclitaxel Pazopanib Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer Active, not recruiting
NCT01582204 Phase I Pazopanib Sunitinib Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma Active, not recruiting
NCT01575548 Phase III Pazopanib Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Active, not recruiting
NCT02601209 Phase Ib/II Pazopanib Sapanisertib Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Active, not recruiting
NCT02729194 Phase I Pazopanib Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma Active, not recruiting
NCT02560012 Phase II Everolimus Sorafenib Temsirolimus Axitinib Sunitinib Pazopanib Personalized Targeted Inhibitors Treatment in Renal Cell Cancer Terminated
NCT02014636 Phase I Pazopanib Pembrolizumab Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC) Active, not recruiting
NCT02979899 Phase III Pazopanib Carotuximab + Pazopanib A RANDOMIZED PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA (TAPPAS) Recruiting
NCT01392183 Phase II Diphenhydramine Temsirolimus Pazopanib Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC) Active, not recruiting
NCT02551718 Phase I Bosutinib Irinotecan romidepsin Busulfan Melphalan Nilotinib Crizotinib Cytarabine Mitoxantrone Dasatinib Pazopanib Paclitaxel Clofarabine Hydroxyurea Tretinoin Carfilzomib Nelarabine Bexarotene Pentostatin Everolimus Cabozantinib Mercaptopurine Methotrexate Cladribine Thioguanine Daunorubicin Ponatinib Etoposide Afatinib Gefitinib Gemcitabine Regorafenib Arsenic trioxide Trametinib Imatinib Erlotinib Dabrafenib Decitabine Axitinib Azacitidine Ruxolitinib Fludarabine Lapatinib Ceritinib Sirolimus Sorafenib Lomustine Sunitinib Cabazitaxel Temsirolimus Topotecan Bortezomib Pralatrexate High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia Recruiting
NCT01767636 Phase II Pazopanib Pazopanib in Treating Patients With Metastatic Non-Clear Cell Kidney Cancer Active, not recruiting
NCT01158521 Phase II Pazopanib Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer Completed
NCT02300545 Phase II Pazopanib Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy Recruiting
NCT01339871 Phase I Vorinostat Pazopanib Phase I Study of Pazopanib and Vorinostat Completed
NCT02307474 Phase I Pazopanib A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer Withdrawn
NCT03200717 Phase II Pazopanib Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment Recruiting